Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (EUROLIGHT) (EUROLIGHT)
- Conditions
- Dry Age-related Macular Degeneration
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- LumiThera, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT06351605
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)
- Conditions
- Dry Age-related Macular Degeneration
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- LumiThera, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06229665
- Locations
- 🇺🇸
Retina Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Florida Eye Clinic, Altamonte Springs, Florida, United States
Study of Photobiomodulation Effect on Electroretinogram Outcomes in Dry Age-Related Macular Degeneration
- Conditions
- Age Related Macular Degeneration
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- LumiThera, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04522999
- Locations
- 🇺🇸
Perich Eye Center, New Port Richey, Florida, United States
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
- Conditions
- Dry Age-related Macular Degeneration
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- LumiThera, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT04065490
- Locations
- 🇺🇸
Retina Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Florida Eye Clinic, Altamonte Springs, Florida, United States
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE II)
- Conditions
- Dry Age-related Macular Degeneration
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- LumiThera, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT03878420
- Locations
- 🇫🇷
Institut ophtalmologique de l'Ouest- Clinique jules VERNE, Nantes, France
🇩🇪Universitätsklinikum Freiburg- Klinik für Augenheilkunde, Freiburg, Germany
🇩🇪Klinik fur Ophthalmologie, Universitatsklinikum Schleswig-Holstein, Kiel, Germany
- Prev
- 1
- 2
- Next
News
Alcon Acquires LumiThera's Photobiomodulation Device for Dry AMD Treatment
Alcon announced the acquisition of LumiThera, Inc. and its photobiomodulation device for treating early and intermediate dry age-related macular degeneration, expanding beyond its traditional surgical focus.
LumiThera's Valeda Light Delivery System Shows Extended Vision Benefits in Dry AMD Patients Over 4.5 Years
LumiThera's Valeda Light Delivery System, FDA-authorized in November 2024, demonstrated sustained vision improvement of over one line on the eye chart in more than 60% of dry AMD patients through 4.5 years of follow-up.
LumiThera's Valeda Light Delivery System Shows Sustained Vision Improvement in Dry AMD Patients
LumiThera's Valeda Light Delivery System, the first FDA-authorized non-invasive treatment for dry AMD, demonstrated sustained vision improvement of more than 5 letters on eye charts over 24 months in the LIGHTSITE IIIB extension study.
FDA Approves Light Therapy System for Dry Age-Related Macular Degeneration
The FDA has granted marketing authorization to LumiThera's Valeda Light Delivery System, a photobiomodulation (PBM) system, as the first treatment for dry age-related macular degeneration (AMD).
FDA Authorizes LumiThera's Valeda Light Delivery System for Dry AMD
The FDA has granted marketing authorization to LumiThera's Valeda Light Delivery System, marking the first authorized treatment for vision loss in dry age-related macular degeneration (AMD).
FDA Approves Valeda Light Delivery System for Dry Age-Related Macular Degeneration
The FDA has approved LumiThera's Valeda Light Delivery System, marking the first therapeutic option for adult patients with dry age-related macular degeneration (AMD).
FDA Approves LumiThera's Valeda Light Delivery System for Dry AMD
The FDA granted de novo authorization to LumiThera's Valeda Light Delivery System, marking the first approved treatment for vision loss related to dry age-related macular degeneration.
LumiThera's Valeda Light Delivery System Receives FDA Authorization for Dry AMD
LumiThera's Valeda Light Delivery System has been authorized by the FDA for treating vision loss in patients with dry age-related macular degeneration (AMD).